

IL-31, IL-32 and IL-33 may serve as diagnosis biomarkers in gastric cancer

Qinghua Liu MD, PhD^{1,2}, Jiwei Zhang MD³, Lei Xia¹, Steven G Wise⁴, Brett D. Hambly, MBBS, PhD^{2,5} *Kun Tao MD PhD⁵ and *Shisan Bao MD, PhD^{2,5}


¹Department of Pathology, Xuzhou Medical University, 221000, China

²Discipline of Pathology, ⁴Discipline of Physiology, School of Medical Sciences, Faculty of Medicine and Science, Charles Perkins Centre, D17, The University of Sydney, NSW 2006, Australia


³Department of Surgery, Songjiang Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China

⁵Tongren Hospital, Shanghai Jiaotong University, School of Medicine, Shanghai, 200336, China


Supplementary Figure 1 Correlation of IL-31, IL-32 and IL-33 expression with clinicopathological parameters of tumour size, lymph node metastasis, tumour differentiation and tumour invasion depth subtypes of GC




Supplementary Figure 2 Correlation of IL-31, IL-32 and IL-33 expression with clinicopathological parameter of TNM subtype of GC and IL-31 expression with gender subtype of GC




Supplementary Figure 3 Survival analysis of IL-31, IL-32 and IL-33 for prognosis of subtypes of GC patients



Supplementary Figure 4 Survival analysis of IL-31, IL-32 and IL-33 for prognosis of subtypes of GC patients




Supplementary Figure 5 Survival analysis of IL-31, IL-32 and IL-33 for prognosis of subtypes of GC patients




SuSupplementary Figure 6 Survival analysis of combination of IL-31, IL-32 and IL-33 for prognosis of GC

IL-31 combined with IL-33



IL-31 combined with IL-32



IL-32 combined with IL-33

